other-cancer

BET inhibitor drugs keep failing—new research reveals why and points to a solution.

BET inhibitors (targeting BRD2 and BRD4 proteins) have shown promise in cancer research but frequently disappointing results in clinical trials. This study reveals that BRD2 and BRD4 have distinct, non-overlapping functions. Current BET inhibitors that block both simultaneously may disrupt cellular…

BET inhibitor drugs keep failing—new research reveals why and points to a solution.

Understanding this functional divergence suggests that isoform-selective BET inhibitors—targeting only BRD4 or only BRD2—might achieve better therapeutic results. This could rescue an entire class of cancer drugs that has struggled clinically.

Key Findings

BRD2 and BRD4 have distinct, non-overlapping cellular functions
Current BET inhibitors blocking both simultaneously may cause contradictory effects
Isoform-selective targeting (BRD4-only or BRD2-only) may improve efficacy
Explains why promising preclinical BET inhibitor results often fail in clinical trials
Validates selective BET inhibitor development as a research priority

Implications

Drug developers should focus on isoform-selective BET inhibitors rather than pan-BET inhibitors. Clinical trial design for BET inhibitors should consider isoform selectivity. This insight could unlock the therapeutic potential of an important class of epigenetic cancer drugs.

Caveats

ScienceDaily press release; limited detail; abstract-only. Specific cancer types studied and experimental models not specified. Clinical implications require prospective validation. Peer-reviewed publication status not confirmed from this abstract.

Source: ScienceDaily Cancer — 2026-04-09

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

BET inhibitor drugs keep failing—new research reveals why and points to a solution.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database